What is Test/Tren/EQ Mix 400?
Test/Tren/EQ Mix 400 is a ready-made oil solution of three compounds: 150mg testosterone enanthate, 150mg boldenone undecylenate (Equipoise) and 100mg trenbolone enanthate per ml, 400mg/ml in total. One vial holds 10 ml and needs no mixing. All three esters are long, so two injections per week are enough.
Testosterone provides the base, boldenone a slow second building compound and trenbolone the strongest but also most demanding part. Trenbolone and boldenone come from veterinary medicine and were never approved for humans. Not a beginner blend: the tren share sets the side-effect profile.
This information is for research and educational purposes only. No medical advice.
Comparison
One, two or three compounds
Which compounds each oil contains, as stated in the TPD lexicon. Tap a card to open its entry.
Simplified: the same compounds do not mean the same amount per ml. Every extra compound brings its own side effects.
How it works
All three compounds activate the androgen receptor. Trenbolone binds it much more strongly than testosterone, is not aromatized to estradiol and also acts on the progesterone receptor, which can favor prolactin effects. Boldenone aromatizes weakly and stimulates red blood cell production, while testosterone aromatizes normally.
Half-lives are about 4 to 5 days (enanthate) and about two weeks (undecylenate). The full effect builds over several weeks. In turn, side effects also fade only slowly after stopping.
Where it acts
One receptor, several organs
Tap a point or a card. Grey = effect seen in trials.
- Hypothalamus and pituitary
LH and FSH suppressed as long as testosterone was raised8
Observed in trials - Testes
Sperm production suppressed: no sperm in 65 percent after 6 months, recovery within months after stopping9
Observed in trials - Blood
Haemoglobin and haematocrit rose with the testosterone dose, more in older men3
Observed in trials - Liver and blood lipids
HDL cholesterol fell by about 60 percent under several anabolic steroids at once6
Observed in trials - Heart
Pumping function lower in long-term users (52 vs 63 percent), more coronary plaque7
Observed in trials - Skeletal muscle
Muscle size in arms and legs and strength increased, most with training1
Observed in trials - Skin
Acne in 28 of 100 users, breast tissue growth in 195
Observed in trials
Targets in the ChEMBL database11
Compound CHEMBL1200335: one recorded mechanism, agonist with direct binding to the human receptor.
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Agonist, direct binding
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
Injection
Intramuscular into the glute, thigh or shoulder, with a thick needle to draw up and a thin one (23G to 25G) to inject. Disinfect the stopper and the site first and rotate sites regularly. Injecting slowly and aspirating first helps against the so-called tren cough, a brief coughing fit right after the injection.
The esters are long, but trenbolone irritates subcutaneous tissue more. Subcutaneous use therefore only at very small volumes and only if well tolerated, otherwise intramuscular.
What the research shows
For testosterone, gains in muscle mass and strength at supraphysiologic doses are well documented (Bhasin, 1996), as is the dose-dependent rise in hemoglobin and hematocrit (Coviello, 2008). Trenbolone is described as a very potent anabolic with reduced androgenic and estrogenic activity, but the data come almost entirely from animal studies (Yarrow, 2010). There are no controlled human studies on boldenone.
Reviews of anabolic steroids show shifted lipids, higher blood pressure plus changes to heart wall and rhythm (Achar, 2010). In a prospective cohort of 100 users every one had at least one side effect and four had a serious event (Smit, 2020). No study exists for the fixed three-way combination.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Strength gain in 10 weeks1
Healthy men, weekly injection of testosterone enanthate or placebo, gain in kg
Trial with testosterone enanthate alone, not with the blend. The abstract gives no figures for the placebo with training group. Mood and behaviour did not change in any group.
Blood lipids under several anabolic steroids6
Change in percent, 19 strength athletes, self-chosen cycle over 8 or 14 weeks
Percentages calculated from the mean values in the abstract: HDL from 1.08 to 0.43 mmol/l, apo-A1 from 1.41 to 0.71 g/l, apo-B from 0.96 to 1.32 g/l, Lp(a) from 189 to 32 U/l. Six weeks after stopping the values had not yet recovered. Nandrolone decanoate alone did not change blood lipids in the second part of the study.
Pumping function of the heart7
Left ventricular ejection fraction in percent, experienced strength athletes aged 34 to 54
Cross-sectional study, users with at least 2 years of total use. Coronary plaque had a median of 3 vs 0, the longer the total use, the more plaque.
Research status
Where the research stands
There is no study on the blend and the registry finds none on trenbolone or boldenone. Shown are registered trials with testosterone enanthate given by injection. As of 26 Oct 2026. 10
- Preclinical Trenbolone: more muscle and bone mass, less fat in various animal species
- Phase 1 9 trials on components, 8 completed, 1 stopped early
- Phase 2 13 trials on components, 8 completed, 1 stopped early
- Phase 3 7 trials on components, 6 completed
- Approval not yet
Show all 23 phase 2, 3 and 4 trials on a timelineHide timeline
NCT00260143 · 61 participants, started May 2003, primary endpoint reached Jun 2006.
Registry entry ↗ · Results not yet in PubMed
NCT00475501 · 60 participants, started Jan 2007, primary endpoint reached Mar 2012. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT01887418 · 39 participants, started Sept 2013, primary endpoint reached Jan 2014.
Registry entry ↗ · Results not yet in PubMed
RESTORE · NCT02090114 · 112 participants, started Aug 2014, primary endpoint reached Nov 2021. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
TRANSFORMER · NCT02286921 · 222 participants, started Jan 2015, primary endpoint reached Oct 2018. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT02229617 · 14 participants, started Jul 2015, primary endpoint reached May 2016.
Registry entry ↗ · Results not yet in PubMed
NCT02777242 · 66 participants, started Jun 2016, primary endpoint reached Aug 2016.
Registry entry ↗ · Results not yet in PubMed
NCT02248701 · 33 participants, started Apr 2017, stopped early Aug 2021. Tests several agents.
HiTeCH · NCT03522064 · 30 participants (planned), started Jul 2018, primary endpoint planned Sept 2026. Tests several agents.
NCT03516812 · 36 participants, started Aug 2018, primary endpoint reached Mar 2021. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT04363164 · 150 participants (planned), started Aug 2020, primary endpoint planned Jul 2027. Tests several agents.
NCT04460872 · 21 participants (planned), started Jan 2021, primary endpoint planned Jan 2026.
WOMBAT · NCT06594926 · 69 participants (planned), started Aug 2024, primary endpoint planned Dec 2026.
NCT00161304 · 44 participants, started Apr 2003, primary endpoint reached Aug 2004.
Registry entry ↗ · Results not yet in PubMed
NCT00965341 · 53 participants, started Sept 2009, primary endpoint reached Sept 2012.
Registry entry ↗ · Results not yet in PubMed
OPTIMen · NCT01275365 · 92 participants, started May 2011, primary endpoint reached Jan 2017.
Registry entry ↗ · Results not yet in PubMed
NCT01595581 · 14 participants, started Apr 2012, primary endpoint reached May 2015.
Registry entry ↗ · Results not yet in PubMed
STEADY · NCT02159469 · 150 participants, started Jul 2014, primary endpoint reached Feb 2015.
Registry entry ↗ · Results not yet in PubMed
NCT02504541 · 133 participants, started Jul 2015, primary endpoint reached Jun 2016.
Registry entry ↗ · Results not yet in PubMed
NCT06689085 · 100 participants (planned), started Mar 2025, primary endpoint planned Mar 2028.
NCT00493987 · 184 participants (planned), started Nov 2002, primary endpoint reached Dec 2009. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT00957801 · 29 participants, started Mar 2009, primary endpoint reached Dec 2015. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
OPS · NCT02734238 · 53 participants, started Apr 2016, primary endpoint reached Dec 2017.
Registry entry ↗ · Results not yet in PubMed
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026, grey = stopped early. Phase 1: 9 trials on safety and pharmacokinetics, not shown as bars.
Side effects
- Prolactin: through its progestogenic action trenbolone can cause prolactin effects, with libido and erection problems. Add prolactin to the bloodwork.
- Lipids: HDL drops markedly and LDL rises. Trenbolone is considered especially unfavorable here.
- Blood pressure and heart: blood pressure and resting heart rate go up, endurance drops noticeably. Measure regularly.
- Sleep: trouble falling asleep, restless sleep and night sweats are typical of the tren share.
- Mood: irritability, restlessness and aggression are reported often.
- Blood count: testosterone and boldenone raise hematocrit and hemoglobin, which increases the risk of thrombosis.
- Other: suppressed hormone axis, acne, hair loss if predisposed, water retention from the testosterone share.
Because the esters are long, these effects cannot be switched off quickly. That is why a low start and bloodwork before, during and after a cycle matter.
Tolerability
Frequency in the HAARLEM study
Out of 100 users, how many had the event. One cohort without a comparison group, participants chose compounds and amounts themselves.
| Event | All 100 users |
|---|---|
| At least one side effect5 | 100% |
| Lower libido after the cycle5 | 58% |
| Fluid retention during the cycle5 | 56% |
| Agitation during the cycle5 | 36% |
| Acne5 | 28% |
| Breast tissue growth (gynecomastia)5 | 19% |
Four participants had a serious event: heart failure, pancreatitis, suicidal thoughts and a flare of ulcerative colitis. One year after the start the observed effects were back at baseline. Effects typical of trenbolone such as sleep problems were not reported separately.5
Storage
Store at room temperature, in the dark and in the original packaging, out of reach of children. Do not put it in the fridge, because cold makes the compounds crystallize out of the oil. If you see crystals, warm the vial in your hand or in warm water and swirl until the solution is clear again. Disinfect the stopper before every draw.